CEO and Head of Research
Dr. Karsdal joined Nordic Bioscience in 2001 and rose to CEO in 2010. Dr. Karsdal has led the development of FDA-approved and supported molecular diagnostics and more than 100 commercialized biomarker assays, including both ELISA assays and assays available on high precision automated platforms.

He has extensive experience with clinical trial design in combination with clinical use of biochemical markers. He has conducted extensive research in the field of fibrosis, rheumatology (rheumatoid arthritis and osteoarthritis), diabetes and more. Dr. Karsdal has published more than 700 peer-reviewed articles and has presented at numerous international scientific conferences. Dr. Karsdal oversees several major partnerships as well as over 150 collaborators in Copenhagen.

H-index: 97. i10-index: 560. Citations: 36654 as of August 2024.

CTO and Director of ImmunoScience
Dr. Bay-Jensen has been with Nordic Bioscience since 2008 - she started as a post-doc and has since been appointed Director of ImmunoScience and Chief Technology Officer (CTO). Through hard work, inventive mentality, and leadership, she has developed novel biomarkers that support precision medicine - a journey that continues. As a researcher, she focuses primarily on biomarkers for rheumatic diseases, which she has worked on for two decades.

H-index: 64. i10-index: 206. Citations: 12159 as of August 2024.

Chief Laboratory Officer, Head of Clinical Laboratory
Dr. Manon-Jensen has been with Nordic Bioscience for more than 8 years, where she was the principal investigator of hemophilia research, discovering novel biomarkers and utilizing her knowledge in the clinical needs for biomarker usage in clinical trials. Today, as the Head of Clinical Laboratory, she is responsible for the daily operations and business of our CAP-certified and CLIA-compliant laboratory.

Her responsibilities include overseeing the measurements we deliver to our customers, biobank, project and data management, LIMS, and custom/CLSI validations. Dr. Manon-Jensen spearheads the only CAP laboratory in Scandinavia and works to differentiate our services from protein array service providers. With her leadership, our lab subscribes to the highest quality standards, and among other things, we are partnering with Roche and advancing IDS i10 platform investments.

H-index: 22. i10-index: 43. Citations: 2975 as of August 2024.

Senior Director of Fibrosis, Hepatic and Pulmonary Research
Dr. Leeming joined Nordic Bioscience in 2004 and assumed the position as Director of Fibrosis in 2010. She has been promoted to Senior Director in 2024. Her focus is on the development of serologically assessed markers to evaluate the extracellular matrix remodeling in patients with pulmonary or hepatic fibrosis for diagnosis or pharmacodynamic evaluation. Dr. Leeming is a principle inventor of PRO-C3 assay, a fibrogenesis marker used in multiple clinical trial studies. She has 280+ peer-reviewed publications.

H-index: 64. I10-index: 180 Citations: 12603 as of August 2024.

Director of Fibrosis, Renal and Cardiovascular Research
Dr. Genovese joined Nordic Bioscience in 2011 and since 2014 has led a group focused on the application of markers for ECM remodeling in renal and cardiovascular disease. Her group's activities range from biomarker discovery and development to clinical and preclinical validation of biomarkers in various chronic kidney diseases (CKD, DKD, IgAN, ADPKD, kidney transplantation) and cardiovascular diseases (HFpEF, atherosclerosis, myocardial infarction, atrial fibrillation).

H-index: 28. i10-index: 42. Citations: 3369 as of August 2024.

Director of Endocrinology and Neuroscience
Dr. Henriksen joined Nordic Bioscience in 2002 and assumed the position of director of endocrinology in 2018. His research focuses on the identification and development of novel peptide therapies for metabolic diseases such as obesity, NASH, and type 2 diabetes, and has led to the patenting and development of two families of peptides, KBPs and OXMs, which are rapidly moving toward clinical development.

H-index: 65, i10-index: 158, Citations 11985 as of August 2024.

Director of Pulmonary Research
Dr. Jannie M. B. Sand has joined the company in 2010. Dr. Sand’s research is dedicated to biomarker development and understanding lung tissue changes in chronic lung diseases, with a specific focus on pulmonary fibrosis and chronic obstructive pulmonary disease (COPD).

The tools developed by Dr. Sand’s team include biomarkers for fibrogenesis, lung tissue destruction, basement membrane repair, and immune cell activity. The team’s research has successfully identified prognostic and pharmacodynamic biomarkers and explores the identification of novel endotypes in chronic lung diseases.

H-index: 24. i10-index: 39. Citations: 2536 as of August 2024.

Director of Oncology
Dr. Willumsen joined Nordic Bioscience in 2012 and assumed the position of department head in oncology in 2016. His research group focuses on the development of blood-based biomarkers to quantify tumor matrix in serum of cancer patients to understand pharmacodynamics/efficacy/resistance mechanisms of treatments. The group's research activities range from biomarker discovery to preclinical and clinical validation of results. In 2022, Dr. Willumsen was appointed as Director of Oncology.

H-index: 26. i10-index: 52. Citations: 2215 as of August 2024.

 

Director of Dermatology
Dr. Holm Nielsen has been with Nordic Bioscience since 2015, where she started as a PhD Fellow and since then has been appointed Scientific Director, focusing on Dermatology. Her dedicated Dermatology team focuses on the development and evaluation of translational blood-based biomarkers to support precision medicine and drug development.

Her favorite collagens are type VI and VII, due to their role in fibrotic and inflammatory skin diseases, such as Hidradenitis Suppurativa, Scleroderma, Atopic Dermatitis, and rare blistering diseases. She is a member of the European Academy of Dermatology & Venerology (EADV), American Society for Matrix Biology (ASMB), and International Society for Matrix Biology (ISMB), where she enjoys discussing scientific stories and sharing her experiences of working in both academia and the biotechnology and pharmaceuticals industry.

H-index: 22. i10-index: 37. Citations: 1828 as of August 2024.

 

Project Director, Clinical Laboratory
Kishwar joined Nordic Bioscience in 2011 after graduating from the Technical University of Denmark. Since 2013 she has been heading the biomarker laboratory associated with the patented tests developed by Nordic Bioscience. Today she leads a team of more than 30 technicians and dedicated project managers providing high quality laboratory services covering all aspects of testing programs for our key customers in the biotech and pharmaceutical industry.

Head of Data Science 
Dr. Bager joined Nordic Bioscience in 2012 - she started as a PhD student and was appointed Head of Datascience in 2019. As Head of Datascience, she and her team focus heavily on biomarker data work and how it can be used to support precision medicine.

H-index: 15. i10-index: 19. Citations: 1011 as of August 2024.

Please don't hesitate to contact us if you have any questions or other inquiries.

Are you interested in learning more about Nordic Bioscience?
Enter your information in the form and a representative will contact you shortly.

By submitting this form you agree to our terms and conditions.